Anti-fungal Drugs Market - Size, Share, Trends, Outlook, and Opportunity Analysis, 2018-2026

  • To Be Published : Sep 2019 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

As the name suggests, anti-fungal drugs are used to treat fungal infections. Common fungal infections such as fungal nail infection, vaginal infection, and ringworm usually occur on the external surface of the body, while certain fungal invasive infections occur inside the tissue of body or in an internal organ such as lungs and brain. Fungal infection is usually associated with a weak immune system, with people suffering from HIV and AIDS, and those undergoing high dosage chemotherapy more susceptible to invasive fungal infections. Anti-fungal drugs work against fungal infections by either killing the fungal cells or by inhibiting their growth. Anti-fungal drugs are broadly classified as topical antifungals, oral antifungals, intravenous antifungals, and intravaginal antifungal pessaries.

As per stats released by Centers for Disease Control and Prevention (CDC), around 1 million people get infected worldwide by cryptococcal meningitis, which is a brain infection caused by fungus Cryptococcus and it subsequently leads to 625,000 deaths. These cases are mainly reported in sub-Saharan Africa. Also, the histoplasmosis infection mostly occurs in the U.S. and some portion of Central and South America. As per CDC’s study, the histoplasmosis is a common infection observed in people with HIV and AIDS. In case of histoplasmosis, late diagnosis and treatment can be fatal.

The global antifungal drugs market recorded double-digit Y-o-Y growth in 2016 and it is expected witness steady growth in the near future. Growth is mainly attributed to increasing prevalence of infections and changing climatic conditions, in turn increasing incidence of fungal infections. Also, Latin and South America have witnessed more growth in anti-fungal drugs revenue than North America in the recent past.

Increasing accessibility to low-cost OTC anti-fungal drugs creates a highly lucrative environment for growth of the global anti-fungal drugs market.

Anti-Fungal drugs market taxonomy:

Global Market by Drug Type

  • Azoles
  • Echinocandins
  • Allylamines
  • Polyenes
  • Others

Global Market by Therapeutic Indication

  • Dermatophytosis
  • Candidiasis
  • Other therapeutic indications

Global Market by Geography

  • North America
  • Latin America
  • Europe
  • Middle East
  • APAC
  • Africa

Growing incidence of antifungal infections and increasing popularity of OTC drugs to drive growth of the antifungal drugs market in near the future

Changing environment conditions and increasing pollution lead to increasing prevalence of various infections. The continuously growing population is also the supportive factor pushing this growth. North America holds the largest market share due to increasing awareness about infections and high investment in R&D in the region. Also, emerging economies in APAC region are projected to witness high growth rate over the forecast period (2017-2024) due to increasing awareness about infectious diseases, increasing R&D activities, and growing target population.

The major factor driving growth of the market is rising popularity of OTC drugs as they are cost effective for the patients and growing advertisement of antifungal drugs for dermal infections like for skin infection is also the helping factor for the growth of antifungal drugs. Also, patent expiration of branded drugs will also lead to market growth. Increased funding for R&D in developed countries and increased focus on product innovation will further augment market growth.

Key Developments

  1. Major companies in the market are focused on various growth strategies such as collaboration and agreement, in order to enhance their market presence. For instance, in June 2017, Basilea Pharmaceutica Ltd., a biopharmaceutical company, entered into agreement with Pfizer, Inc. and Avir Pharma, Inc. for the distribution of Beasilea’s antifungal treatments. Pfizer will manufacture and distribute drugs for treatment of life-threatening invasive mold infections in Russia, Israel, Europe (excluding Nordics), and Turkey.
  2. Key players in the market are focused on various business strategies such as research and development, in order to expand their product portfolio. For instance, in January 2019, SCYNEXIS, Inc., a biotechnology company, announced positive interim result from first interim efficiency analysis of ongoing FURI study. The development of this novel treatment is indicated for fungal treatment.
  3. Key players in the market are involved in various growth strategies such as gaining product approval from regulatory authorities, in order to strengthen their market presence. For instance, in February 2018, Insmed, Inc., a biopharmaceutical company, received the U.S. Food and Drugs Administration (FDA) approval for new drug Arikayce (amikacin liposome inhalation suspension), which was approved limited population pathway for antibacterial and antifungal drugs program.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.